Discussing the Potential of Novel Agents for Treatment of GIST
Winston Tan, MD, discusses the emergence of novel agents for the treatment of patients with gastrointestinal stromal tumors, namely agents like avapritinib and ripretinib, which have shown promise in ongoing clinical trials.<br />
Winston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses the emergence of novel agents for the treatment of patients with gastrointestinal stromal tumors (GIST), namely agents like avapritinib (BLU-285) and ripretinib (DCC-2618), which have shown promise in ongoing clinical trials.
Any drug that has the ability to delay progression of disease is a good treatment option, says Tan. It is also important, however, to find the maximum tolerated dose in clinical trials to limit toxicity in patients with GIST. Another important component to clinical trials is molecular testing. Identifying molecular targets and then hitting those targets may help oncologists to control the disease even longer.
Even with the emergence of promising new agents, physicians should not discount the drugs that are already approved for the treatment of locally advanced GIST in the adjuvant setting. The primary drug is imatinib (Gleevec), which works well for patients withc-KIT
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
